Core Viewpoint - Huafeng Chemical's profitability continues to decline, and its attempt to expand through acquisitions has failed [1][2] Group 1: Acquisition Attempt - Huafeng Chemical announced the termination of its plan to acquire 100% of Huafeng Synthetic Resin and Huafeng Thermoplastic Polyurethane due to lack of shareholder approval [2][3] - The total consideration for the failed transaction was 6 billion yuan in cash and 54 billion yuan in shares, with a proposed issuance of 879 million shares [2] - The valuation of Huafeng Synthetic Resin showed a 506.96% increase, while Huafeng Thermoplastic had a 478.49% increase compared to their book values [3] Group 2: Financial Performance - From 2022 to 2024, Huafeng Chemical's revenue was 258.84 billion yuan, 262.98 billion yuan, and 269.31 billion yuan, with year-on-year changes of -8.75%, 1.60%, and 2.41% respectively [6] - Net profit for the same period was 28.44 billion yuan, 24.78 billion yuan, and 22.20 billion yuan, reflecting a decline of 64.17%, 12.85%, and 10.43% respectively [6] - In Q1 2025, the company reported revenue of 63.14 billion yuan, down 5.15% year-on-year, and net profit of 5.04 billion yuan, down 26.21% [8] Group 3: Industry Context - The spandex industry has transitioned from a peak to a cyclical low, facing oversupply and declining raw material prices, leading to continuous price drops [8][9] - The average price of domestic spandex 40D in 2024 was 26,417.21 yuan per ton, a year-on-year decrease of approximately 17.11% [9] - Despite the challenges, Huafeng Chemical plans to continue expanding its production capacity, with an additional 150,000 tons of spandex expected to be gradually put into production starting in 2025 [9]

事件 Q1 营收稳步增长，期间费用影响利润表现。Q1 公司实现营业收入1.39亿元，同比增长13.90%，归母净 利润108.21 万元，同比下降69.50%，毛利率为24.24%，同比提升2.67pct，净利率为-0.55%，同比下滑 2.92pct。 我们认为Q1 毛利率提升的主要原因是公司基本完成了车间的生产正常化同时毛利率较高的产品销售占 比提升；净利率同比下滑的主要原因是：①子公司华海共同研发投入增多，研发费用同比增加439.10 万 元；②募投项目转固后可转债利息停止资本化导致利息费用增加，财务费用同比增加748.60 万元。 产能大规模投放，有望助力营收快速增长。截至2025 年3 月底，公司固定资产合计为11.30 亿元，相较 2024 年同期增加了9.27 亿元，总规模扩大约5 倍，募投项目"黄体酮及中间体BA 生产建设项目"正式投 产，同时加强华海共同原料药项目和甾体类产业链升级项目的建设，目前已经完成了主体工程的建设， 其中华海共同原料药项目一期工程完成设备调试并启动试生产，二期规划聚焦高端皮质激素原料药产能 储备。 积极开展股份回购，彰显长期发展信心。公司拟使用自有资金及股票回购专项贷 ...